O modelo integrado é construído para moléculas recombinantes, não para peptídeos personalizados em programas de DNA para IND
A via integrada é definida pela expressão recombinante, e essa definição, não é uma lacuna na cobertura do serviço, é o que coloca os peptídeos sintéticos fora dele. A página do programa da Lonza descreve um fluxo de trabalho coordenado do CMC que traz o desenvolvimento de linhas celulares, desenvolvimento de processos e formulações, testes analíticos e documentação regulatória juntos, “minimizando as transferências e alinhando todas as atividades do CMC” (Página do programa Lonza DNA-to-IND, sem data, recuperado 2026). Cada etapa dessa cadeia começa com uma célula transfectada.
O Outubro 2026 a expansão estendeu a mesma cadeia para produtos biológicos não-mAb, adição de anticorpos biespecíficos, Proteínas de fusão Fc e formulações de medicamentos de alta concentração, e avançar o desenvolvimento de formulações de alta concentração mais cedo no processo (Assessoria de mídia Lonza). As classes de moléculas nomeadas são todas formatos recombinantes.
Os pontos de entrada definidos do programa vão desde a construção do vetor e avaliação da capacidade de fabricação, passando pelo DNA, até a toxicidade de substâncias medicamentosas ou lotes de medicamentos., DNA para pesquisar, banco de células mestre ou de produção, transferência de uma linha celular ou processo estabelecido, e substância medicamentosa a granel ou produto purificado, com a opção de execução totalmente integrada ao IND ou pausa em marcos definidos (Página do programa Lonza DNA-to-IND, sem data, recuperado 2026). Um peptídeo sintetizado quimicamente não possui vetor, nenhuma linha celular e nenhuma etapa de transfecção para entrar em.
Os cronogramas declarados pelo fornecedor carregam o mesmo quadro. A tabela de marcos lista seis meses desde a sequência de DNA até IND/IMPD, DNA será toxificado em dois meses e redução precoce do risco em menos de 11 semanas, com uma nota de rodapé limitando a afirmação a “desde a transfecção de DNA até a entrega de módulos CMC habilitadores de IND. Cronogramas típicos. Sujeito aos termos e condições” (Página do programa Lonza DNA-to-IND, sem data, recuperado 2026). O relógio começa na transfecção. Para um peptídeo totalmente sintetizado quimicamente, A transfecção de DNA não é o marco inicial relevante.
As duas estruturas desenham o limite do peptídeo de maneira diferente, e a diferença é a química
Rota de produção, características do produto, indicação e jurisdição influenciam o caminho regulatório. A química pós-cadeia é uma consideração, não é a única variável que decide qual estrutura se aplica.
Os dois regimes então divergem sobre onde um peptídeo modificado chega. A diretriz da EMA aceita derivados naturais de L-aminoácidos protegidos, e em casos justificados fragmentos curtos de peptídeos, como materiais de partida, mas afirma que os fragmentos polipeptídicos submetidos apenas a modificações adicionais limitadas do GMP, tais como ciclização ou conjugação com porções não peptídicas como cadeias de PEG, são intermediários em vez de materiais iniciais. Ele também trata um derivado de PEG ativado, como um éster de NHS, como um intermediário. (Diretriz da EMA, eficaz 1 Junho 2026).
A FDA retirou o 2021 orientação em julho 2026. A modificação ou lipidação por si só não exclui universalmente uma via de medicamento genérico; avaliar a semelhança com o produto de referência, orientação atual específica do produto e os requisitos reais da aplicação. Retirada da FDA e atualização do projeto revisado.
A diretriz da EMA aborda questões relevantes sobre peptídeos sintéticos e qualidade de conjugação. A elegibilidade da via FDA deve ser avaliada separadamente para o produto proposto e o medicamento de referência; the amount of added chemistry does not create a common EMA/FDA exclusion rule.
O que o registro de impurezas e especificações realmente exige de um peptídeo
A peptide’s specification is written from peptide-specific impurity classes and thresholds, not inherited from either adjacent framework. The categories the EMA guideline names are stereoisomers, deletion sequence, truncated sequence and insertion sequence (EMA guideline landing page, eficaz 1 Junho 2026). The thresholds the EMA points to come from Ph. EUR. general monograph 2034: report an impurity above 0.1%, identify above 0.5%, qualify above 1.0%, with no universal numerical limit for unspecified or total peptide-related impurities, which are set product-specifically and justified case by case (Diretriz da EMA, eficaz 1 Junho 2026).
Venda por atacado de peptídeos The thresholds that do not apply are worth stating plainly, because they are a common source of error. Eu Q3A(R2) sets reporting at 0.05%, identification at 0.10% ou 1.0 mg/day and qualification at 0.15% ou 1.0 mg/day for a maximum daily dose at or below 2 g/day (Eu Q3A(R2), current revision). Those numbers are not peptide limits, and the EMA guideline states directly that the Q3A limits “are not applicable” to synthetic peptides.
Conjugation adds attributes that a chain-only specification misses. The EMA guideline requires control of the free unconjugated peptide and the free form of the conjugate moiety, such as free PEG or linker, and states that di-PEGylation, multi-PEGylation and non-site-specific PEGylation products should be adequately controlled (Diretriz da EMA, eficaz 1 Junho 2026). It also requires that all steps of the intermediate synthesis from the defined starting material be performed under GMP, with full process information in Module 3 Section 3.2.S.2.2.
The specification guideline that excludes synthetic peptides is not the frame to reach for. ICH Q6B defines a specification as a list of tests, references to analytical procedures and acceptance criteria, and its impurity taxonomy is built for recombinant expression: cell substrate-derived, cell culture-derived and downstream-derived (Eu Q6B, Etapa 4, 1999). That taxonomy does not transfer to a solid-phase synthesis, where the impurities are enantiomeric and diastereomeric species, partially unprotected amino acids, dipeptides and beta-alanyl impurities (Diretriz da EMA, eficaz 1 Junho 2026).
Onde um especialista agrega valor: triagem de viabilidade antes que a rota seja fixada
The case for an early feasibility check is arithmetic, not preference. Thirty couplings at 99% effective yield give 0.99³⁰, aproximadamente 74% cumulative retention before deprotection, clivagem, purification and isolation losses (Almanaque Farmacêutico). A sequence that couples poorly at three positions loses more than the model predicts, and the loss compounds silently until the crude profile is measured.
That is why route selection is a sequence-specific decision rather than a platform default. UM 2025 review of therapeutic peptide discovery and synthesis reports that chemical synthesis suits peptides of 50 residues or fewer, where truncated sequences, racemisation and side reactions require HPLC purification, while biological synthesis suits longer sequences but introduces Peptídeo 1 Fabricante host-cell proteins, endotoxins and misfolding (Zheng et al., Interno. J.. Mol. Ciência., 2025). The same review notes that minor deviations in amino acid sequence, post-translational modification or impurity profile can critically affect pharmacological activity, pharmacokinetics and immunogenicity.
Scale changes the control points, não apenas o tamanho do lote. Custom peptide synthesis spans milligrams for discovery and assay standards, grams for process development, toxicology and early clinical work, tens to hundreds of grams or around a kilogram per batch for clinical and niche products, and kilograms to multi-kilograms per batch for commercial API, with sequence, modification and purity requirements mattering as much as nominal batch size (Almanaque Farmacêutico, 18 Poderia 2026). Coupling completeness, deprotection and cleavage behaviour, crude impurity burden, preparative purification loadability and counter-ion or salt form are the points that decide whether a campaign scales, and they are cheapest to test before the route is locked.
Modificado, peptídeos marcados e conjugados são onde o modelo integrado para
<figure class="blog-chart" style="max-width:640pixels;margin:1.5rem auto;font-size:12pixels;line-height:1.3;color:inherit"> <svg viewBox="0 0 560 380" style="max-width: 100%; height: auto; font-family: 'Inter', system-ui, sans-serif; color: #1e293b; --chart-muted: #64748b;" role="img" aria-labelledby="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title 2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc"> <style> /* The renderer puts the chart in an iframe whose element background is black, and the iframe is a different shape to the chart, so the letterbox bands showed as black frames around it (prod 09-22). The document inside the iframe is transparent by default; painting it here covers the element background, and when the chart is inlined instead this matches nothing. Keep angle brackets out of this block: a style element inside an SVG is parsed as foreign content, so one stray bracket discards every rule in it. */ html, body { background: #ffffff; margin: 0; } @media (prefers-reduced-motion: reduzir) { * { animation: none !important; transition: none !important; } } </style> <rect x="0" y="0" width="560" height="380" rx="8" fill="#ffffff" /> <title id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title">2025 peptide and oligonucleotide CDMO revenue split</title> <desc id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc">peptide and oligonucleotide CDMO revenue split: values for Peptides, Oligonucleotides. 2025 peptide and oligonucleotide CDMO revenue split. donut data: Peptídeos 66.7; Oligonucleotides 33.3.Source: Pesquisa Grand View, Peptídeo & Oligonucleotide CDMO Market 2026.</desc> <text x="280.0" y="29" text-anchor="meio" font-size="18" font-weight="800" fill="currentColor">2025 peptide and oligonucleotide CDMO revenue split</texto> <path d="M 238.00 93.00 UM 92 92 0 1 1 158.23 230.83 eu 192.91 210.91 UM 52 52 0 1 0 238.00 133.00 Z" fill="#f97316" /> <path d="M 158.23 230.83 UM 92 92 0 0 1 238.00 93.00 eu 238.00 133.00 UM 52 52 0 0 0 192.91 210.91 Z" fill="#38bdf8" /> <text x="238" y="182" text-anchor="meio" font-size="22" font-weight="800" fill="currentColor">100</texto> <text x="238" y="201" text-anchor="meio" font-size="10" fill="var(--chart-muted, currentColor)">total</texto> <rect x="360" y="96" width="11" height="11" fill="#f97316" /> <text x="378" y="105" font-size="11" fill="currentColor">Peptides 66.7</texto> <rect x="360" y="124" width="11" height="11" fill="#38bdf8" /> <text x="378" y="133" font-size="11" fill="currentColor">Oligonucleotides 33.3</texto> <text x="280.0" y="366" text-anchor="meio" font-size="10" fill="var(--chart-muted, currentColor)">Fonte: Pesquisa Grand View, Peptídeo & Oligonucleotide CDMO Market (2026)</texto> </svg> </figure>
The starting-material logic is where the two regimes separate most sharply. The EMA guideline requires the choice of starting material for the conjugation component to be justified under ICH Q11, and states that activation of a suitable PEG starting material is part of the manufacturing process, so an activated PEG derivative such as an NHS ester may be considered an intermediate rather than a starting material (Diretriz da EMA, eficaz 1 Junho 2026). It also expects separate documentation for each supplier of the conjugation moiety or linker, and a compiled specification elaborated by the peptide-conjugate manufacturer.
The Synthesis Of Aspirin The practical consequence is that a program adding labels, vinculadores, PEG chains or lipid tails is running a chemistry project alongside a peptide project. O 2025 review’s comparison table makes the split explicit: chemical synthesis enables non-natural amino acids, isotopic labelling and site-specific modifications, while biological synthesis is limited to natural amino acids unless genetic or enzymatic engineering is added (Zheng et al., Interno. J.. Mol. Ciência., 2025). That flexibility is exactly what a recombinant-expression platform cannot absorb. Peptídeo 2 Fabricante
O handoff é um problema de especificação e transferência de método, não é um problema de cronograma
When a peptide program moves between partners, the transferable asset is the specification and the validated methods behind it, and the governing validation guideline is shared with the biologic route. Eu Q2(R2), adopted 1 novembro 2023 with an error correction on 30 novembro 2023, applies to analytical procedures used for release and stability testing of drug substances and products, covering assay, potência, pureza, impurity as a quantitative or limit test, and identity, and can be applied phase-appropriately during clinical development (Eu Q2(R2), adopted 1 novembro 2023). Its scope is defined by use case rather than molecule type.
The peptide-specific side of the package is less standardised. The EMA guideline expects full information in Module 3 Section 3.2.S.2.2, including flowchart, process description with all process steps, raw materials and manufacturing process controls, and requires all intermediate synthesis steps from the defined starting material to be performed under GMP (Diretriz da EMA, eficaz 1 Junho 2026). For a conjugated peptide, that package also carries the conjugation chemistry description and the supplier documentation for each conjugation moiety or linker.
Microbial and endotoxin control are calculated, not fixed. The endotoxin limit is derived as K/M, where K is 5 EU/kg/hour for most parenteral routes, 0.2 EU/kg/hour for intrathecal and 100 EU/m²/hour for body-surface-area dosing, with M the maximum recommended human dose per kg per hour (Capítulo Geral da USP <85>, current chapter, recuperado 2026). Teste de esterilidade sob USP <71> is qualitative: Custom Pna Synthesis it detects viable microbial contamination and does not demonstrate absolute sterility or quantify contamination (USP <71> Testes de esterilidade, harmonisation text). Neither limit travels as a number in a transfer document; both travel as methods and calculations.
The evidence base does not support a benchmark for transfer failure or delay. No primary or peer-reviewed figure for technology-transfer failure rates was located, so the risk is best argued from the regulatory mechanism: the specification, the validated methods and the GMP process description are what a receiving site must reproduce, and their completeness determines how much of the program is rebuilt.
Uma regra de decisão para análises de parcerias
The rule below turns the regulatory boundary into a partnering test. It is written as an if/then list so it can be applied directly in a vendor review.
If the candidate is a chemically synthesized peptide of roughly 50 residues or fewer with no post-chain modification, then a specialist synthesis and analytics partner is the fit, and an integrated recombinant pathway is the wrong entry point.
For a modified construct, identify the relevant conjugation chemistry, site specificity, starting materials and likely impurities. Controls for free PEG or multiple PEG attachments apply when PEG chemistry is involved, not automatically to every isotope label or noncanonical residue.
If the sequence has known difficult segments, then run the feasibility and route check before the route is fixed, porque 30 couplings at 99% per-step efficiency retain only about 74% of the chain before purification (Almanaque Farmacêutico, 18 Poderia 2026).
If the program is a recombinant biologic, then the integrated model is the right frame, and the peptide-specific thresholds and conjugation requirements in this article do not apply.
The market context supports treating peptide programs as a distinct buying decision rather than a subset of biologics. The peptide and oligonucleotide CDMO market was USD 3.1 bilhão em 2025 and is forecast at USD 8.1 bilhão por 2033 em um 12.9% CAGR, with peptides holding 66.7% de 2025 revenue (Pesquisa Grand View, 2026 edição, 2025 ano base). Both figures come from a report vendor, and the CDMO number covers peptides and oligonucleotides combined. The wider peptide therapeutics market was USD 140.9 bilhão em 2025, forecast at USD 294.6 bilhão por 2033 em um 8.7% CAGR (Pesquisa Grand View, 2026 edição, 2025 ano base). The biologics CDMO market the integrated model sits in is projected at USD 62 billion with an 11.7% CAGR (GlobalData via GlobeNewswire, 14 outubro 2026). All three are report-vendor models. Oligopeptide Synthesis
Perguntas frequentes
Os cronogramas anunciados por Lonza se aplicam a um programa de peptídeos?
Não, because the clock those timelines measure starts at DNA transfection, and the formats named in the same material are recombinant: monoclonal antibodies, bispecifics and Fc-fusion proteins (Página do programa Lonza DNA-to-IND, sem data, recuperado 2026). A chemically synthesized peptide never passes through that step, so the schedule is not a benchmark a peptide team can borrow. What transfers between the two is the regulatory destination, not the route or the calendar.
Um especialista pode levar um programa para o IND sem um provedor integrado?
Sim. The Module 3 e Q2(R2) obligations do not change with the size of the partner, so the difference is not what gets filed but who holds the specification and the validated method set at filing. A specialist can hold both, provided the discovery to development peptide handoff is documented as a controlled transfer rather than an informal one. What an integrated provider adds is convenience of coordination, not a regulatory category the specialist cannot occupy.
E se um programa já estiver a meio caminho de um caminho integrado?
Transfer the specification, the methods and the comparative batches instead of restarting. Restarting discards the analytical history that supports the specification, and rebuilding it costs more than moving it. The transfer package is the unit of work: product-specific limits, validated release and stability methods, and the process description that shows where the defined starting material sits.
Conclusão
A peptide program does not inherit the small-molecule impurity framework, and it does not inherit the biologic one. Eu Q3A(R2) excludes peptides, ICH Q6B excludes synthetic peptides, and the EMA guideline effective 1 Junho 2026 supplies the peptide-specific framework in their place, with Ph. EUR. 2034 thresholds and product-specific limits. That is the structural fact behind the partnering question, and it is independent of any vendor’s timeline.
The integrated DNA-to-IND model is a coherent answer to a recombinant problem. Its named molecule classes are mAbs, bispecifics and Fc-fusion proteins, its entry points begin at vector construction, and its clock starts at DNA transfection. A chemically synthesized peptide has none of those inputs, so the fit question is answered before cost or speed enters the discussion.
The next step is a feasibility assessment on the specific sequence, run before the route is fixed. Sequence-level coupling risk, modification chemistry, scale target and the applicable specification framework determine whether a specialist partner is the right choice, and the arithmetic of per-step yield makes that assessment cheapest at the earliest stage.
